×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BMRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
05:49 am
bmrn
BioMarin Pharmaceutical (BMRN) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
BioMarin Pharmaceutical (BMRN) was upgraded by Truist Financial Corporation to "strong-buy".
3/20
02:28 pm
bmrn
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks [Yahoo! Finance]
Low
Report
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks [Yahoo! Finance]
3/18
08:39 pm
bmrn
How The BioMarin (BMRN) Story Is Shifting With Voxzogo Risks And The Amicus Deal [Yahoo! Finance]
Low
Report
How The BioMarin (BMRN) Story Is Shifting With Voxzogo Risks And The Amicus Deal [Yahoo! Finance]
3/17
09:03 am
bmrn
BioMarin discontinues dosing in certain Voxzogo trials after safety concern [Yahoo! Finance]
Low
Report
BioMarin discontinues dosing in certain Voxzogo trials after safety concern [Yahoo! Finance]
3/16
12:08 pm
bmrn
BioMarin Pharmaceutical (BMRN) had its "outperform" rating reaffirmed by Wolfe Research.
Low
Report
BioMarin Pharmaceutical (BMRN) had its "outperform" rating reaffirmed by Wolfe Research.
3/16
09:52 am
bmrn
BioMarin stops mid-stage trials of bone disorder treatment [Yahoo! Finance]
Low
Report
BioMarin stops mid-stage trials of bone disorder treatment [Yahoo! Finance]
3/13
11:01 pm
bmrn
BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents [Yahoo! Finance]
Medium
Report
BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents [Yahoo! Finance]
3/13
05:34 am
bmrn
BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/23/2026
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
Report
-0.5%
biomarin pharmaceutical inc.
10/27/2025
04:03 pm
bmrn
biomarin pharmaceutical inc.
MISS
Report
1.6%
biomarin pharmaceutical inc.
8/4/2025
04:02 pm
bmrn
biomarin pharmaceutical inc.
BEAT
Report
2.7%
biomarin pharmaceutical inc.
5/1/2025
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
Report
-1.1%
biomarin pharmaceutical inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/26
04:10 pm
bmrn
Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VANGUARD GROUP INC
Neutral
Report
Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: VANGUARD GROUP INC
3/19
04:53 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 18 Filed by: Davis George Eric
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 18 Filed by: Davis George Eric
3/19
04:51 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Guyer Charles Greg
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Guyer Charles Greg
3/19
04:49 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Mueller Brian
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Mueller Brian
3/19
04:34 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Hardy Alexander
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 17 Filed by: Hardy Alexander
3/18
01:42 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Hubbard Cristin
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Hubbard Cristin
3/18
01:40 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Friberg Gregory R
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 16 Filed by: Friberg Gregory R
3/17
08:51 pm
bmrn
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: Guyer Charles Greg
Low
Report
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: Guyer Charles Greg
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/14
Form 4 BIOMARIN PHARMACEUTICAL For: May 10 Filed by: BIENAIME JEAN JACQUES
7.5%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
TOP News Decliners
3/11
Form 4 BIOMARIN PHARMACEUTICAL For: Mar 03 Filed by: BIENAIME JEAN JACQUES
-12.3%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: